Boston Children’s Technology Development Fund launches 2017 funding cycle
Letters of Intent (LOI) are due to Technology Development Fund by emailing email@example.com on Feb. 8, 2017.
The Technology Development Fund (TDF), managed by the Technology & Innovation Development Office (TIDO), was created in 2009 to translate Boston Children’s laboratory and clinical research into new therapeutics, medical devices, diagnostics and Healthcare IT products to benefit our patients and the broader public.
TDF provides selected projects with:
- Financial Support
- Access to an external advisory board of industry experts in product development
- Technical support provided by a network of preferred contract research organizations (CROs)
- Active management of the projects and external relationships
In 2015, The TDF will continue to offer two different funding levels ($50,000 and $150,000) based on the current stage of development of the technology.
To apply for funding, applicants must submit a Letter of Intent (LOI) to TDF and an invention disclosure must be on file at TIDO.
Selected applicants will be contacted by April 2017 and invited to submit a full proposal. In addition to the written proposal, all selected applicants will be asked to give a 15 minute presentation on their proposed project to the advisory board.
To learn more about TDF, please join us for an informational lunch seminar:
Wednesday, January 18, 2017, 12 - 1 pm
Karp 7 Conference room
Pizza will be provided, so please RSVP to firstname.lastname@example.org
TDF by the numbers:
• 8 funding cycles completed with $7.2 M committed to support 71 individual projects
• TDF project development has led to:
o $26 M of follow on funding from foundations, government, and private sources
o 7 new companies with $61 M in seed funding
o 10 licenses/options
o $2.1 M in licensing revenue received
o A network of 45 contract research organizations for drug, medical device and software development
For additional information, please visit our website.
For questions, please contact Carla Haslauer, PhD at: